Study details
Enrolling now
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
Louisiana State University Health Sciences Center in New Orleans
NCT IDNCT05266898ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
250
Study length
about 3.6 years
Ages
18–65
Locations
1 site in LA
About this study
This trial is testing how well the Gardasil-9 vaccine works to create antibodies against human papillomavirus (HPV) in adults with HIV. The goal is to see if people living with HIV develop a similar antibody response as those without HIV, and whether the vaccine provides short-term clinical benefit against HPV infections.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Human papillomavirus 9-valent vaccine, recombinant
- 2.Receive human papillomavirus vaccine, recombinant
PhasePhase 4
DrugHuman papillomavirus 9-valent vaccine
Routeinjection
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
vaccine
Drug routes
injection
Body systems
Immune, Infectious